Roth Capital Analysts Give Nektar Therapeutics (NKTR) a $45.00 Price Target

Nektar Therapeutics (NASDAQ:NKTR) has been given a $45.00 price objective by investment analysts at Roth Capital in a research report issued on Monday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Roth Capital’s price objective would indicate a potential upside of 21.29% from the stock’s previous close.

A number of other analysts have also recently weighed in on the stock. ValuEngine raised shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. William Blair reaffirmed an “outperform” rating on shares of Nektar Therapeutics in a research note on Tuesday, July 18th. Jefferies Group LLC reaffirmed a “buy” rating and set a $23.00 target price on shares of Nektar Therapeutics in a research note on Friday, July 21st. BidaskClub cut shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 23rd. Finally, Cowen and Company started coverage on shares of Nektar Therapeutics in a research note on Tuesday, November 7th. They issued an “outperform” rating on the stock. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $32.91.

Shares of Nektar Therapeutics (NASDAQ:NKTR) opened at $37.10 on Monday. Nektar Therapeutics has a one year low of $11.41 and a one year high of $41.34. The company has a debt-to-equity ratio of 2.91, a quick ratio of 3.99 and a current ratio of 4.14.

Nektar Therapeutics (NASDAQ:NKTR) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.37 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $0.16. The firm had revenue of $152.90 million for the quarter, compared to analysts’ expectations of $126.50 million. Nektar Therapeutics had a negative net margin of 42.08% and a negative return on equity of 190.68%. The company’s revenue was up 321.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.32) earnings per share. equities analysts forecast that Nektar Therapeutics will post -0.78 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This report was originally published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://www.truebluetribune.com/2017/11/14/roth-capital-analysts-give-nektar-therapeutics-nktr-a-45-00-price-target.html.

In related news, CAO Jillian B. Thomsen sold 2,648 shares of the business’s stock in a transaction on Wednesday, August 16th. The shares were sold at an average price of $19.32, for a total value of $51,159.36. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Stephen K. Doberstein sold 396,323 shares of the business’s stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $29.00, for a total transaction of $11,493,367.00. Following the completion of the transaction, the senior vice president now owns 52,016 shares in the company, valued at approximately $1,508,464. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,024,757 shares of company stock worth $25,974,361. 5.44% of the stock is owned by company insiders.

Hedge funds have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Nektar Therapeutics by 14.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,603 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 692 shares during the period. LS Investment Advisors LLC lifted its holdings in Nektar Therapeutics by 8.8% in the second quarter. LS Investment Advisors LLC now owns 6,594 shares of the biopharmaceutical company’s stock valued at $129,000 after buying an additional 535 shares during the period. Mark Sheptoff Financial Planning LLC lifted its holdings in Nektar Therapeutics by 79.4% in the third quarter. Mark Sheptoff Financial Planning LLC now owns 6,100 shares of the biopharmaceutical company’s stock valued at $146,000 after buying an additional 2,700 shares during the period. Flinton Capital Management LLC lifted its holdings in Nektar Therapeutics by 75.7% in the second quarter. Flinton Capital Management LLC now owns 7,872 shares of the biopharmaceutical company’s stock valued at $154,000 after buying an additional 3,392 shares during the period. Finally, Riverhead Capital Management LLC lifted its holdings in Nektar Therapeutics by 78.7% in the second quarter. Riverhead Capital Management LLC now owns 8,754 shares of the biopharmaceutical company’s stock valued at $171,000 after buying an additional 3,854 shares during the period. Institutional investors and hedge funds own 94.97% of the company’s stock.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply